share_log

海吉亞醫療:截至二零二四年六月三十日止六個月中期業績公告

HYGEIA HEALTH: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEX ·  Aug 29 10:14

Summary by Moomoo AI

海吉亞醫療控股有限公司公布截至2024年6月30日止六個月的中期業績,顯示集團收入較2023年同期增加35.4%,達到人民幣2,381.9百萬元。醫院業務收入增長37.2%,至人民幣2,307.5百萬元。毛利和EBITDA分別增加32.5%及28.7%,而資本支出則下降39.0%。非國際財務報告準則經調整淨利潤增加15.5%,達到人民幣400.6百萬元。此外,董事會決定動用回購授權,在公開市場上以不超過人民幣200.0百萬元總價格回購股份,但暫不建議宣派任何股息。
海吉亞醫療控股有限公司公布截至2024年6月30日止六個月的中期業績,顯示集團收入較2023年同期增加35.4%,達到人民幣2,381.9百萬元。醫院業務收入增長37.2%,至人民幣2,307.5百萬元。毛利和EBITDA分別增加32.5%及28.7%,而資本支出則下降39.0%。非國際財務報告準則經調整淨利潤增加15.5%,達到人民幣400.6百萬元。此外,董事會決定動用回購授權,在公開市場上以不超過人民幣200.0百萬元總價格回購股份,但暫不建議宣派任何股息。
Hygeia Health Holdings Limited announced its interim performance for the six months ended June 30, 2024, showing a 35.4% increase in group revenue compared to the same period in 2023, reaching RMB 2,381.9 million. Hospital business revenue increased by 37.2% to RMB 2,307.5 million. Gross profit and EBITDA increased by 32.5% and 28.7% respectively, while capital expenditures decreased by 39.0%. Adjusted net profit under non-international financial reporting standards increased by 15.5%, reaching RMB 400.6 million. In addition, the board of directors decided to use the repurchase authorization to repurchase shares in the open market at a total price not exceeding RMB 200.0 million, but currently does not recommend declaring any dividends.
Hygeia Health Holdings Limited announced its interim performance for the six months ended June 30, 2024, showing a 35.4% increase in group revenue compared to the same period in 2023, reaching RMB 2,381.9 million. Hospital business revenue increased by 37.2% to RMB 2,307.5 million. Gross profit and EBITDA increased by 32.5% and 28.7% respectively, while capital expenditures decreased by 39.0%. Adjusted net profit under non-international financial reporting standards increased by 15.5%, reaching RMB 400.6 million. In addition, the board of directors decided to use the repurchase authorization to repurchase shares in the open market at a total price not exceeding RMB 200.0 million, but currently does not recommend declaring any dividends.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more